| Business Summary | | Chantal
Pharmaceutical
Corporation
and
its
subsidiaries
are
primarily
engaged
in
the
research,
development
and
marketing
of
compounds
for
use
as
dermatological
and
skin
care
consumer
products.
Ethocyn,
one
of
three
principal
patented
compounds
for
which
the
Company
has
exclusive
manufacturing
and
distribution
rights,
is
presently
being
marketed
by
the
Company
as
a
cosmetic
product
that
helps
improve
the
appearance
of
aged
skin.
The
Company
operates
in
one
industry
segment,
the
development
and
marketing
of
cosmetic
and
skin
care
products.
Cyoctol
and
Metcyclor
are
the
Company's
two
other
principal
patented
compounds.
Cyoctol
is
a
non-steroidal,
anti-androgen
that
is
in
various
stages
of
clinical
trials
for
the
treatment
of
certain
androgen
mediated
disorders,
such
as
acne,
male
pattern
baldness
and
keloids.
Metcyclor
is
in
final
stages
of
pre-clinical
development
for
the
treatment
of
certain
cancers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Chantal
is
engaged
in
the
research,
development
and
marketing
of
innovative
compounds
for
use
as
dermatological
and
skin
care
consumer
products.
For
the
nine
months
ended
3/31/98,
revenues
decreased
51%
to
$3.5
million.
Net
loss
decreased
34%
to
$4.3
million.
Revenues
reflect
a
decrease
on
sales
to
Stanton
and
the
absence
of
export
sales
to
Taiwan.
Lower
loss
reflects
a
decrease
in
advertising
expenditures,
consulting
services
and
promotional
expenditures. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1997 Pay | |
| Chantal Burnison, 46 Chairman,
CEO | $290K | Marc Dworkin, 51 Pres | 180K | Yvette Lamprecht, 29 CFO | 101K | Polly Bergen, 66 COO,
Director | -- | Joseph DeKama, 57 Exec.
VP | -- | Dollar amounts are as of 30-June-1997 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|